(PFE) Pfizer - Overview
Stock: Medicines, Vaccines, Biosimilars, Injectables, Oncology
| Risk 5d forecast | |
|---|---|
| Volatility | 25.3% |
| Relative Tail Risk | -5.13% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.36 |
| Alpha | 1.54 |
| Character TTM | |
|---|---|
| Beta | 0.437 |
| Beta Downside | 0.856 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.27% |
| CAGR/Max DD | -0.18 |
EPS (Earnings per Share)
Revenue
Description: PFE Pfizer February 28, 2026
Pfizer (NYSE:PFE) is a global biopharmaceutical leader that discovers, develops, manufactures, markets and distributes a broad portfolio of medicines and vaccines across therapeutic areas such as cardiovascular disease, infectious disease, oncology, immunology and rare diseases. Its flagship brands include Eliquis, Prevnar, Comirnaty, Paxlovid and a growing line-up of biosimilars and mRNA-based candidates, while the firm also offers contract-manufacturing services to a diverse customer base that spans hospitals, pharmacies and government agencies.
In its most recent fiscal year (2025), Pfizer reported revenue of $100.3 billion, a 4.2 % increase YoY, driven largely by strong oncology sales (e.g., Ibrance and Tivdak) and the resurgence of its biosimilar pipeline. Adjusted earnings per share rose to $4.15, and the company reinvested $12.5 billion into R&D, reflecting a continued focus on next-generation mRNA therapeutics and antibody-drug conjugates. COVID-19 product sales continued to decline, falling 78 % from their 2022 peak, underscoring the need for diversification beyond pandemic-related revenue.
Key sector drivers for Pfizer include the aging global population, which fuels demand for chronic-disease treatments, and the accelerating adoption of biologics and mRNA platforms that are reshaping drug development economics. Pricing pressure from payers and heightened regulatory scrutiny remain headwinds, while strategic collaborations-such as the AI-focused partnership with Boltz, PBC and ongoing alliances with BioNTech, Bristol-Myers Squibb and Merck KGaA-provide pathways to accelerate innovation and improve cost efficiency.
For a deeper quantitative dive, you may want to explore additional analytics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 7.77b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.25 > 1.0 |
| NWC/Revenue: 9.45% < 20% (prev 11.57%; Δ -2.12% < -1%) |
| CFO/TA 0.06 > 3% & CFO 11.70b > Net Income 7.77b |
| Net Debt (63.65b) to EBITDA (15.10b): 4.22 < 3 |
| Current Ratio: 1.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (5.69b) vs 12m ago -0.30% < -2% |
| Gross Margin: 70.33% > 18% (prev 0.67%; Δ 6967 % > 0.5%) |
| Asset Turnover: 29.69% > 50% (prev 29.82%; Δ -0.13% > 0%) |
| Interest Coverage Ratio: 3.20 > 6 (EBITDA TTM 15.10b / Interest Expense TTM 2.67b) |
Altman Z'' 4.14
| A: 0.03 (Total Current Assets 42.90b - Total Current Liabilities 36.98b) / Total Assets 208.16b |
| B: 0.55 (Retained Earnings 114.61b / Total Assets 208.16b) |
| C: 0.04 (EBIT TTM 8.53b / Avg Total Assets 210.78b) |
| D: 1.80 (Book Value of Equity 207.89b / Total Liabilities 115.64b) |
| Altman-Z'' Score: 4.14 = AA |
Beneish M
| DSRI: none (Receivables none/14.78b, Revenue 62.58b/63.63b) |
| GMI: 0.95 (GM 70.33% / 66.76%) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: 0.98 (Revenue 62.58b / 63.63b) |
| TATA: -0.02 (NI 7.77b - CFO 11.70b) / TA 208.16b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of PFE shares?
Over the past week, the price has changed by +0.74%, over one month by +2.25%, over three months by +10.21% and over the past year by +11.39%.
Is PFE a buy, sell or hold?
- StrongBuy: 7
- Buy: 2
- Hold: 15
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the PFE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.4 | 4.3% |
| Analysts Target Price | 28.4 | 4.3% |
PFE Fundamental Data Overview February 28, 2026
P/E Forward = 9.2421
P/S = 2.4622
P/B = 1.6604
P/EG = 13.7734
Revenue TTM = 62.58b USD
EBIT TTM = 8.53b USD
EBITDA TTM = 15.10b USD
Long Term Debt = 56.55b USD (from longTermDebt, two quarters ago)
Short Term Debt = 3.15b USD (from shortTermDebt, last quarter)
Debt = 64.80b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 63.65b USD (from netDebt column, last quarter)
Enterprise Value = 205.28b USD (154.08b + Debt 64.80b - CCE 13.60b)
Interest Coverage Ratio = 3.20 (Ebit TTM 8.53b / Interest Expense TTM 2.67b)
EV/FCF = 22.62x (Enterprise Value 205.28b / FCF TTM 9.07b)
FCF Yield = 4.42% (FCF TTM 9.07b / Enterprise Value 205.28b)
FCF Margin = 14.50% (FCF TTM 9.07b / Revenue TTM 62.58b)
Net Margin = 12.42% (Net Income TTM 7.77b / Revenue TTM 62.58b)
Gross Margin = 70.33% ((Revenue TTM 62.58b - Cost of Revenue TTM 18.57b) / Revenue TTM)
Gross Margin QoQ = 69.97% (prev 74.95%)
Tobins Q-Ratio = 0.99 (Enterprise Value 205.28b / Total Assets 208.16b)
Interest Expense / Debt = 1.10% (Interest Expense 711.0m / Debt 64.80b)
Taxrate = 21.0% (US default 21%)
NOPAT = 6.74b (EBIT 8.53b * (1 - 21.00%))
Current Ratio = 1.16 (Total Current Assets 42.90b / Total Current Liabilities 36.98b)
Debt / Equity = 0.70 (Debt 64.80b / totalStockholderEquity, last quarter 93.10b)
Debt / EBITDA = 4.22 (Net Debt 63.65b / EBITDA 15.10b)
Debt / FCF = 7.01 (Net Debt 63.65b / FCF TTM 9.07b)
Total Stockholder Equity = 91.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.69% (Net Income 7.77b / Total Assets 208.16b)
RoE = 8.52% (Net Income TTM 7.77b / Total Stockholder Equity 91.23b)
RoCE = 5.77% (EBIT 8.53b / Capital Employed (Equity 91.23b + L.T.Debt 56.55b))
RoIC = 4.45% (NOPAT 6.74b / Invested Capital 151.63b)
WACC = 5.56% (E(154.08b)/V(218.88b) * Re(7.53%) + D(64.80b)/V(218.88b) * Rd(1.10%) * (1-Tc(0.21)))
Discount Rate = 7.53% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.34%
[DCF] Terminal Value 84.03% ; FCFF base≈9.38b ; Y1≈7.65b ; Y5≈5.40b
[DCF] Fair Price = 17.91 (EV 165.47b - Net Debt 63.65b = Equity 101.82b / Shares 5.69b; r=5.90% [WACC]; 5y FCF grow -22.08% → 2.90% )
EPS Correlation: -42.40 | EPS CAGR: -21.29% | SUE: 0.94 | # QB: 10
Revenue Correlation: -58.19 | Revenue CAGR: -9.63% | SUE: 0.37 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.70 | Chg7d=-0.011 | Chg30d=-0.026 | Revisions Net=+0 | Analysts=18
EPS current Year (2026-12-31): EPS=2.96 | Chg7d=-0.005 | Chg30d=-0.012 | Revisions Net=-1 | Growth EPS=-8.1% | Growth Revenue=-2.3%
EPS next Year (2027-12-31): EPS=2.83 | Chg7d=+0.007 | Chg30d=-0.020 | Revisions Net=-1 | Growth EPS=-4.3% | Growth Revenue=-3.5%
[Analyst] Revisions Ratio: +0.00 (4 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.9% (Discount Rate 7.9% - Earnings Yield 5.0%)
[Growth] Growth Spread = -4.1% (Analyst -1.1% - Implied 2.9%)